No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
CGTX Cognition Therapeutics
- 2.060
- -0.130-5.94%
Trading Jun 18 13:05 ET
82.52MMarket Cap-2239P/E (TTM)
2.220High2.020Low90.38KVolume2.220Open2.190Pre Close188.96KTurnover0.27%Turnover RatioLossP/E (Static)40.06MShares2.98052wk High2.86P/B69.75MFloat Cap0.90052wk Low--Dividend TTM33.86MShs Float13.800Historical High--Div YieldTTM9.13%Amplitude0.900Historical Low2.090Avg Price1Lot Size
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Chardan Research Initiates Cognition Therapeutics With Buy Rating, $11 Price Target
Cognition Therapeutics (CGTX) has an average buy rating and a price target range of $5 to $11, according to analysts polled by Capital IQ. Price: 1.9200, Change: +0.09, Percent Change: +4.92
Cognition Therapeutics Price Target Announced at $11.00/Share by Chardan Capital
Cognition Therapeutics Price Target Announced at $11.00/Share by Chardan Capital
Chardan Capital Initiates Coverage On Cognition Therapeutics With Buy Rating, Announces Price Target of $11
Chardan Capital analyst Daniil Gataulin initiates coverage on Cognition Therapeutics with a Buy rating and announces Price Target of $11.
Cognition Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/29/2024 352.49% HC Wainwright & Co. → $10 Initiates Coverage On → Buy 03/28/2024 126.24% B. Riley Secur
Express News | Cognition Therapeutics Inc : H.c. Wainwright Initiates Coverage With Buy Rating; Target Price $10
Buy Rating Affirmed for Cognition Therapeutics on Promising Alzheimer's Drug Candidate CT1812
Comments
$Cognition Therapeutics(CGTX.US$
NEWS
Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease
Cognition Therapeutics (NASDAQ: CGTX) released the eighth episode of its Conversations video podcast titled “Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease.” This episode explores how beta amyloid (Aβ) oligomers lead to synaptic dysfunction and cognitive decline. The podcast discusses recent researc...
NEWS
Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease
Cognition Therapeutics (NASDAQ: CGTX) released the eighth episode of its Conversations video podcast titled “Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease.” This episode explores how beta amyloid (Aβ) oligomers lead to synaptic dysfunction and cognitive decline. The podcast discusses recent researc...
$Cognition Therapeutics(CGTX.US$ Cognition Therapeutics To Be Issued US Patent Number 11,981,636 Titled "COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES (INCLUDING ALZHEIMER'S DISEASE AND COGNITIVE DECLINE)"
$Cognition Therapeutics(CGTX.US$
NEWS
Cognition Therapeutics To Be Issued US Patent Number 11,981,636 Titled "COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES (INCLUDING ALZHEIMER'S DISEASE AND COGNITIVE DECLINE)"
NEWS
Cognition Therapeutics To Be Issued US Patent Number 11,981,636 Titled "COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES (INCLUDING ALZHEIMER'S DISEASE AND COGNITIVE DECLINE)"
3
$Cognition Therapeutics(CGTX.US$ Cognition Therapeutics Inc: Top-Line Results Are Expected in Second Half of 2024 After Last Participants Have Completed Six Months of Treatment
2
2
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg